Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note published on Monday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Trading Down 0.5 %

NASDAQ CHEK opened at $0.82 on Monday. Check-Cap has a 12 month low of $0.76 and a 12 month high of $3.45. The company’s 50-day moving average price is $1.26 and its 200-day moving average price is $1.77. The stock has a market cap of $4.78 million, a PE ratio of -0.27 and a beta of 0.39.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.